Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control

Per Munck af Rosenschold\textsuperscript{1,2}*, Michael J. Zelefsky\textsuperscript{3}, Aditya P. Apte\textsuperscript{1}, Andrew Jackson\textsuperscript{1}, Jung Hun Oh\textsuperscript{1}, Elliot Shulman\textsuperscript{3}, Neil Desai\textsuperscript{3,4}, Margie Hunt\textsuperscript{1}, Pirus Ghadjar\textsuperscript{3}, Ellen Yorke\textsuperscript{1} and Joseph O. Deasy\textsuperscript{1}

Abstract

**Background:** To determine if reduced dose delivery uncertainty is associated with daily image-guidance (IG) and Prostate Specific Antigen Relapse Free Survival (PRFS) in intensity-modulated radiotherapy (IMRT) of high-risk prostate cancer (PCa).

**Methods:** Planning data for consecutive PCa patients treated with IMRT \((n = 67)\) and IG-IMRT \((n = 35)\) was retrieved. Using computer simulations of setup errors, we estimated the patient-specific uncertainty in accumulated treatment dose distributions for the prostate and for posterolateral aspects of the gland that are at highest risk for extra-capsular disease. Multivariate Cox regression for PRFS considering Gleason score, T-stage, pre-treatment PSA, number of elevated clinical risk factors (T2c+, GS7+ and PSA10+), nomogram-predicted risk of extra-capsular disease (ECD), and dose metrics was performed.

**Results:** For IMRT vs. IG-IMRT, plan dosimetry values were similar, but simulations revealed uncertainty in delivered dose external to the prostate was significantly different, due to positioning uncertainties. A patient-specific interaction term of the risk of ECD and risk of low dose to the ECD \((p = 0.005)\), and the number of elevated clinical risk factors \((p = 0.008)\), correlate with reduced PRFS.

**Conclusions:** Improvements in PSA outcomes for high-risk PCa using IG-IMRT vs. IMRT without IG may be due to improved dosimetry for ECD.

**Keywords:** Image-guided, Radiotherapy, Prostate cancer, High risk disease, IMRT, Tumor control probability

Background

Image Guided Radiation Therapy (IGRT) refers to the use of imaging to improve dose localization to targeted tissue regions [1]. Daily IGRT registered to fiducial markers in prostate cancer (PCa) radiotherapy allows geometric accuracy review and compensatory treatment couch shift. This reduces uncertainty of dose delivery, and is essential for highly conformal intensity modulated radiotherapy (IMRT).

Concurrent reduction in target volume margins to reduce normal tissue dose [1, 2] and facilitation of dose-escalation, which is associated with improved Prostate Specific Antigen (PSA) Relapse Free Survival (PRFS) [3–8], are previously theorized mechanisms whereby IGRT may improve the therapeutic ratio of IMRT. In the era of increasingly conformal RT, a number of publications have shown that the geometrical specifics of planning and delivery parameters may influence treatment outcome. Specifically, larger Rectum Cross Section (RCS) area at treatment simulation has been associated with inferior biochemical tumor control outcomes [9, 10]. In another cohort, where an IGRT protocol was used, no association between large RCS
and worse PRFS was present [11]. As a caution, one study even found that the introduction of daily IGRT coupled with a reduced PTV margin was associated with an inferior PRFS [12].

At our institution, however, we initially introduced IG without altering target margins, dose, or planning directives and yet detected an improved PRFS for high-risk PCa [13]. Use of IG has been associated with reduced urinary and gastrointestinal-related toxicity [13–15].

High-risk prostate cancer is commonly associated with disease in the postero-lateral aspect of the gland, which comprises the peripheral zone and beyond it. The purpose of the current study was to quantitatively model variances in the dose delivery at areas of the prostate and in the area of extracapsular disease (ECD) in order to identify a potential mechanism for the benefit of IG-IMRT in PCa. We hypothesized that IGRT reduced statistical deviations from adequate irradiation that were occurring in the non-IG cohort, resulting in a reduced risk of under-dosing the posterolateral aspect of the prostate and at the site of likely ECD and improving disease control.

**Methods**

**Patients and treatment protocol**

We reviewed 102 NCCN (National Comprehensive Cancer Network v2008.2) high-risk prostate cancer patients consecutively treated at our institution during a transition to IGRT during 2005–2009, which represents the same high-risk cohort reported previously [13]. The patient characteristics are shown in Table 1 (Additional file 1: Table S1).

Radiotherapy was planned in 1.8 Gy fractions to a total of 86.4 Gy using IMRT. The prostate, central part of the prostate (encompassing the urethra), rectum, bladder, bladder wall, were delineated. A planning target volume (PTV) margin of 1.0 cm except posteriorly where the margin was 0.6 cm was assigned to the clinical target volume (CTV), which encompassed the prostate plus seminal vesicles (see Additional file 2 additional details). Follow-up evaluations after IMRT were performed at 3 (1st year) to 6 months intervals. The median follow-up time was 3.0 (range: 0.3–4.8) and 4.9 (range: 0–7.4) years for the IG-IMRT and IMRT cohorts, respectively. PRFS was calculated using the Phoenix definition (nadir+ 2 ng/mL).

| Table 1 Patient characteristics | IG-IMRT | IMRT | p-value (Fisher) |
|----------------------------------|---------|------|-----------------|
| Pre-treatment PSA (ng/ml)*        | Number  | Percent | Number  | Percent |                      |
| < 10                             | 15      | 42.9  | 41      | 62.1    | 0.169               |
| 10–20                            | 9       | 25.7  | 10      | 15.2    |                      |
| > 20                             | 11      | 31.4  | 15      | 22.7    |                      |
| Total Gleason score*             |         |       |         |         | 0.082               |
| < 7                              | 3       | 8.8   | 5       | 7.5     |                      |
| 7                                | 10      | 29.4  | 8       | 11.9    |                      |
| > 7                              | 21      | 61.8  | 54      | 80.6    |                      |
| T-stage*                         |        |       |         |         | 0.026               |
| T1c-T2a                          | 10      | 28.6  | 34      | 52.3    |                      |
| T2b                              | 9       | 25.7  | 6       | 9.2     |                      |
| > T2b                            | 16      | 45.7  | 25      | 38.5    |                      |
| Radiation dose delivered         |         |       |         |         | 1.000               |
| 86.4 Gy                          | 34      | 97.1  | 66      | 98.5    |                      |
| 84.6 Gy                          | 0       | 0.0   | 1       | 1.5     |                      |
| 82–8 GY                          | 1       | 2.9   | 0       | 0.0     |                      |
| Age (y)                          |         |       |         |         | 0.071               |
| < 70                             | 12      | 34.3  | 37      | 55.2    |                      |
| > 70                             | 23      | 65.7  | 30      | 44.8    |                      |
| Neoadjuvant ADT                  |         |       |         |         | 1.000               |
| Yes                              | 30      | 42.9  | 57      | 42.5    |                      |
| No                               | 5       | 7.1   | 10      | 7.5     |                      |
| Positioning                      |         |       |         |         | < 0.001             |
| Prone                            | 1       | 2.9   | 65      | 97.0    |                      |
| Supine                           | 34      | 97.1  | 2       | 3.0     |                      |
| Number of risk factors**         |         |       |         |         | 0.215               |
| 1                                | 10      | 28.6  | 31      | 46.3    |                      |
| 2                                | 18      | 51.4  | 27      | 40.3    |                      |
| 3                                | 7       | 20.0  | 9       | 13.4    |                      |

**Abbreviations:** PSA Prostate Specific Antigen, ADT Androgen Deprivation Therapy

*One, one and two of the patients lacked information on pre-treatment PSA, Gleason score and T stage, respectively

**Counting the number of risk factors as defined as PSA > 10, T Stage >T2c and total Gleason score > 7**

Derivation of the risk of extra-capsular disease

It is well known that positive margins in radical prostatectomy are associated with inferior PSA outcomes; hazard ratios of 1.2–3.7 have been reported. Further, a posterolateral positive surgical margin was observed to confer the greatest risk of recurrence [16]. This prompted us to study the dosimetry of the prostate capsule and beyond it in the peripheral zone, which in general is where the disease is located. For the purpose of this analysis, we defined 5 regions beyond the prostate gland. Each region concentrically isotropically expanded out 0.25 cm from the dorsal half of the CTV, which encompasses the posterolateral aspect of the prostate and the neurovascular bundle region. However, the regions were made such that they were not intersecting with the rectum (see Fig. 1, and Additional file 2 for a detailed description). Each patient’s T-stage, Gleason score and pre-treatment PSA were used to estimate the
probability of ECD in the first region using a logistic regression model previously presented [17]. Two different data sets [18, 19] were identified that provides estimates of the risk of ECD as a function of distance out from the prostate gland (i.e. CTV). For this study, we used the average risk estimated from these two data sets to derive the risk of ECD in regions 2–5 (i.e. 0.25–1.00 cm out from the CTV).

Simulation of treatments based on position uncertainty
See Additional file 2 for additional details on the procedure. Planned and delivered radiation dose distributions differ due to residual geometrical variations in setup, as well as other potential factors, such as anatomic changes during a course of radiotherapy. We attempted to quantify this difference for both the IMRT and IG-IMRT cohorts by means of simulating the positioning uncertainty, following a similar procedure as [20]. The patients’ planned dose distribution, CT data set and contours were extracted from the in-house treatment planning software and imported into the CERR software [21]. Using a programming script, the simulated isocenter position was sampled using a systematic and a random error using positioning uncertainty data from [22]. For IG-IMRT patients, however, the systematic error stems from lack of imaging isocentricity and misalignment vs. the radiation isocenter.

For both positioning protocols, 200 bootstrap samples (simulated treatments) for each patient were created. The list of positioning errors for each bootstrap were then used to shift the dose distribution and the total dose distribution was thus calculated by summation of the dose delivered for all the fractions. Also, the variance of the mean dose for each bootstrap sample for each patient was calculated for the PTV and CTV. Finally, using the bootstrap samples, the probability of a patient receiving a dose 10 Gy lower than the prescription dose to the posterolateral regions (defined above) was calculated.

Statistical analysis
In this exploratory analysis, two-sided tests were used and unadjusted p-values of 0.05 or less were considered significant. Calculations were performed using R (v3.0.1). We investigated if RCS was associated with the dose to
the posterior aspect of the PTV margin (the posterior quarter of the PTV defined from the cranio-caudal axis) (Spearman).

First, we were screened the covariates related to ECD for association with PRFS using univariate Cox regression. This pre-selection method was used to reduce the risk of over-fitting the ECD data, which were internally correlated. The ECD-related covariates included the patient-specific bootstrap risk of low dose to the posterolateral regions of the prostate gland (5 regions), and the risk of ECD in the same region, as well as the interaction parameter of the risk of ECD involvement and low dose (10 Gy or less lower than the prescription dose). Of these 15 covariates, the covariate with the strongest association with the PRFS in univariate analysis was referred to as the "candidate ECD descriptor". Subsequently, the RCS, the bootstrap median dose to the CTV and the PTV, GS, T-stage and pre-treatment PSA, the number of clinical (NCCN) risk factors (i.e. GS 7+, PSA 10+ and T2c+) along with the candidate ECD descriptor were introduced in an univariate and multivariate Cox regression model for PRFS. The forward approach was used, stepwise introducing significant ($p < 0.05$) univariate parameters in the multivariate model (SPSS v19, IBM). The Cox model was generated in the same fashion for the whole cohort and subsequently for the IMRT cohort only. Kaplan-Meier plots were generated for the whole cohort (IG-IMRT and IMRT) and the IMRT cohort only, where patients were split into unfavourable and favourable groups based on the respective Cox models.

**Results**

A comparison of dosimetric data for treatment plans and simulations (corrected for the actual number fractions delivered) for the IG-IMRT and IMRT cohorts is found in Table 2. The treatment plan average dose to the CTV was systematically higher, while the average dose to the posterior aspect of the PTV margin and the RCS were systematically lower and higher, respectively, for the IMRT cohort. For the whole cohort, increasing RCS was significantly associated with decreasing dose to the posterior aspect of the PTV ($p < 0.001$).

Using the simulation approach, the median of the average dose to the CTV dropped less than 0.1 Gy and 1.3 Gy for the IG-IMRT and IMRT groups, respectively ($p < 0.001$). The 'dose leakage' out of the posterior part of the PTV margin was larger, 0.2 and 3.0 Gy for the IG-IMRT and IMRT cohorts, respectively. This dose leakage effect is shown graphically for a typical patient, where the variance of the dose is displayed in colour scale (Fig. 1). The expected 'dose leakage' out of the CTV was quite limited, even for IMRT. However, a subset of individual simulation cases had a very substantial dose leakage out of the prostate (i.e. more than 10% dose fall off) and these were more likely to have large simulated systematic positioning errors. For the IMRT cohort, a systematic positioning error that translated into an observed isocenter offset anteriorly was most strongly associated with increase dose leakage (Spearman $\rho = 0.44$, $p < 0.001$), which is due to movement of the prostate into the sharp dose-gradient towards the rectum. In addition, but much less pronounced, an offset of the isocenter in the caudal direction was associated with a dose leakage ($\rho = 0.03$, $p < 0.001$). A three-dimensional positioning error was strongly associated with dose leakage ($\rho = 0.38$, $p < 0.001$), as well as the absolute deviation anterior-posteriorly ($\rho = 0.23$, $p < 0.001$), laterally ($\rho = 0.03$, $p < 0.001$) and cranio-caudally ($\rho = 0.31$, $p < 0.001$).

The interaction term of the probability of a 10 Gy dose lower than the prescription and the risk of ECD for the region at about 1 cm from the CTV was found be the ECD covariate with the strongest correlation with PRFS through univariate Cox regression (Additional file 1: Table S2). The multivariate Cox regression analysis demonstrated that the number of NCCN clinical risk factors and the interaction term of the probability of a 10 Gy

| Parameter | IG-IMRT | IMRT |
|-----------|---------|------|
|           | Min     | 25% quartile | Median | 75% quartile | Max | Min | 25% quartile | Median | 75% quartile | Max | p-value (Mann-Whitney) |
| Rectal cross-section (cm²) | 0.55 | 5.21 | 6.51 | 7.77 | 14.95 | 3.93 | 6.51 | 8.31 | 11.00 | 19.44 | 0.001 |
| PLAN: Average dose to the CTV | 83.29 | 87.10 | 88.17 | 88.52 | 89.80 | 85.58 | 87.77 | 88.54 | 89.22 | 91.24 | 0.008 |
| PLAN: Average dose to the dorsal part of the PTV margin | 79.48 | 80.73 | 83.36 | 84.20 | 86.77 | 76.43 | 79.89 | 81.46 | 83.33 | 87.03 | 0.005 |
| SIMULATION: Expected dose to the whole CTV | 83.25 | 87.03 | 88.12 | 88.46 | 89.70 | 84.26 | 86.51 | 87.24 | 88.26 | 90.07 | 0.039 |
| SIMULATION: Variance of dose to whole CTV | 0.24 | 0.29 | 0.34 | 0.38 | 0.74 | 1.55 | 2.16 | 2.48 | 2.88 | 3.89 | 0.000 |
dose lower than the prescription and the risk of ECD for the region at about 1 cm from the CTV was associated with a reduced PRFS (see Table 3, Additional file 1: Table S1 and Table S2). Increasing RCS was also significantly associated with a decreased dose to the posterior part of the PTV, but RCS alone was not associated with PSA failure for the combined group or for the IG-IMRT or IMRT groups individually. A Cox model for the IMRT cohort only is found in Additional file 1: Table S3, where the number of NCCN risk factors and the risk of ECD were significant in the multivariate analysis. Kaplan-Meier plots are found in Fig. 2 for the whole cohort (a) and for the (b) IMRT only cohort, respectively. In each of the plots, patients were split (median) into favourable and unfavourable groups based on the respective survival function estimated using the respective Cox model. Log rank statistics revealed significantly different PSA relapse free survival for favourable and unfavourable patients for the whole cohort \( (p = 0.017) \) and for the IMRT patients \( (p = 0.002) \).

### Discussion

This is the first report to our knowledge to suggest that the observed improved PRFS with IG-IMRT could be related to the risk delivering a low dose to the dorsal region adjacent to the peripheral zone, which is the region known to be most likely harbouring disease. The derived hazard ratios related to ECD for our data are on par with those from data reported for radical prostatectomy series with positive margins [16]. Our finding emphasizes the significance of integration of IG radiation therapy treatment protocols for high-risk prostate cancer, where risk of disease progression and ECD are largest. The clinical decision was to keep the same PTV margins after the introduction of IGRT. Our analysis suggests that a reduction of the posterolateral PTV margins without target position correction could have reduced the PRFS of these high-risk patients as a direct result of target under-dosage. By comparison of the Cox model for the IMRT and the whole cohort, we find that the risk of low dose is the dose-volume factor that distinguishes the PSA outcome for IG-IMRT from IMRT patients. When inspecting the series of K-M curves in Fig. 2, we find that the use of IGRT appear to lift the unfavourable K-M curve up for the whole cohort towards the favourable group for IMRT only cohort. Our findings are supported by previous analyses, where the dose coverage near the prostate gland appear to have impacted the PSA outcomes for high risk prostate cancer patients [23, 24].

The positioning uncertainty data can be used to estimate the uncertainty of dose distributions for the IMRT and IG-IMRT cohorts by means of computer simulations. From these calculations we may observe statistical measures from the patient-specific probability distributions. We cannot, however, in retrospect identify the true positioning errors or the exact delivered dose distributions. We cannot, however, in retrospect identify the true positioning errors or the exact delivered dose distributions, only potential scenarios for the patients. An additional limitation of our study is that 3D distributions, only potential scenarios for the patients. The positioning uncertainty data can be used to estimate the uncertainty of dose distributions for the IMRT and IG-IMRT cohorts by means of computer simulations. From these calculations we may observe statistical measures from the patient-specific probability distributions. We cannot, however, in retrospect identify the true positioning errors or the exact delivered dose distributions, only potential scenarios for the patients.

### Table 3

Univariate and Multivariate Cox model analysis data predicting for PRFS. Significant covariates in the univariate and multivariate model are printed in bold typeface.

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | p-value             | Hazard Ratio          | 95% CI                 | p-value |
| Overall model                    | 0.001               |                       |                       |         |
| T-Stage                          | 0.083               | ns                    |                       |         |
| Gleason                          | 0.127               | ns                    |                       |         |
| Pre-RT PSA                       | 0.012               | ns                    |                       |         |
| Number of NCCN risk factors<sup>a</sup> | 0.008               | 2.15                  | (1.17–3.95)            | 0.013   |
| Rectal Cross-section             | 0.558               | ns                    |                       |         |
| Neo-adjuvant HT                  | 0.395               | ns                    |                       |         |
| Expected dose to the CTV         | 0.143               | ns                    |                       |         |
| Candidate ECD descriptor<sup>b</sup> | 0.005               | 3.88                  | (1.26–1.99)            | 0.018   |

<sup>a</sup>Pre-treatment PSA10+, G7+ and T2c+

<sup>b</sup>Interaction term: probability of low dose (10 Gy less than prescription dose) and probability of extra-capsular disease at about 1 cm dorso-laterally of the prostate gland
was strongly associated to the probability of biopsy verified residual disease. Interestingly, limiting the analysis to only the IMRT cohort still yields a strong correlation the risk of ECD and with the number NCCN risk factors (Additional file 1: Table S3). Generally, the ECD related covariates show correlation with PRFS (Additional file 1: Table S2), though the covariates are also (unsurprisingly) internally correlated (data not shown). The selection of a 10 Gy dose drop is relatively arbitrary but was selected to represent a substantial dose reduction, likely to affect local control; however selecting 8 or 12 Gy produces similar results (data not shown). The multivariate Cox model of PRFS offers no proof in itself, but may offer a potential explanation of the observed difference between IG-IMRT and IMRT PSA outcomes and could be considered in the hypothesis generation for further studies. A full patterns of failure analysis might be helpful in that respect; this is however beyond the scope of the present work.

The patient characteristics for the high-risk PCa IG-IMRT and IMRT groups selected for analysis were similar and only the T stages were significantly higher for the IG-IMRT group (Table 1). A single patient in the IG-IMRT group showed a markedly reduced lower delivered dose than the majority due to the exclusion of two fractions. One difference between the two cohorts was that IG-IMRT patients we treated in supine position while IMRT patients were mostly treated in prone position, which has probably influenced the positioning uncertainty somewhat [28]. Using the simulations of positioning uncertainty, we find that there were only minor differences with respect to the average dose to the CTV delivered to the IG-IMRT and IMRT cohorts, as shown in Fig. 3. The average dose posterolaterally is however substantially reduced for the IMRT cohort. This means that for most patients the delivered dose distribution inside the CTV will be close to the plan even without IGRT. However, without the use of IG there is a certain risk for a substantial reduction of the dose, which is practically non-existing for IG-IMRT patients.

In contrast to previous reports [9, 10] we found no correlation of RCS and the risk of PSA failure in this cohort of patients. However, the RCS data in our cohort were mostly below the 11 cm² cut-off used previously [9]. Further, we are unable to confirm the observation that use of IG removes the association of RCS and PSA

![Fig. 2 PSA relapse-free survival for high-risk prostate cancer patients for the whole cohort (left) and the IMRT cohort only (right). The respective Cox models were used to select the patients with favorable and unfavorable outcome, respectively.](image)

![Fig. 3 Dose fall-off in the posterolateral direction, averaged over all patients for all treatment plans. This is also averaged between the left and right regions for each patient. The 0 cm distance point is the average of the whole CTV. The probability of the existence of extra-capsular disease for the whole cohort of high-risk patients is plotted onto the secondary axis.](image)
failure [11]. Consistent with this analysis, RCS was not a predictor for PSA failure when using IG [29]. We note that the finding in this exploratory retrospective analysis should be verified in a larger study, and that there is still a need for a mechanistic tumor control probability model including a more realistic method to account for non-uniform intra-prostate tumor burden. A potential approach to refine the current model is to use e.g. magnetic resonance imaging to attempt to contour the gross tumor [30] as well as any suspected extra-prostatic disease. However, for the current data set pre-treatment magnetic resonance scans were only available for a subset of patients.

Conclusion
In this study we find that the potential for large, though infrequent, setup errors in fractional delivery have the potential to be a primary cause for the outcomes difference between IMRT and IG-IMRT. This strengthens the hypothesis of improved outcome by use of fiducial-based IGRT, and supports the notion that all radiotherapy treatments should be preferably accompanied with some form of adequate image guidance of the prostate position that would be sufficient to rule out significant setup errors.

Additional file

Additional file 1: Table S1. The patient characteristics, for patients experiencing PSA relapse and control, respectively. Table S2. UNIVARIATE COX MODELS FOR THE CANDIDATE ECE DESCRIPTOR. The selected candidate with the strongest association with PSA relapse is marked (*). Table S3. Univariante and Multivariate Cox model analysis data predicting for PRFS for Non-IGRT patients ONLY. The multivariate model improved by the inclusion of the ECD descriptor (p=0.036). (ZIP 487 kb)

Additional file 2: Generating treatment bootstrap samples from random positioning uncertainty for IG-IMRT and IMRT treated patients. (PDF 462 kb)

Abbreviations
CTV: Clinical target volume; ECD: Extra-capsular disease; GS: Gleason Stage; IG: Image-guidance; IGRT: Image Guided Radiation Therapy; IMRT: Intensity-modulated radiotherapy; KM: Kaplan-Meier; NCCN: National Comprehensive Cancer Network; PCA: High-risk prostate cancer; PRFS: Prostate Specific Antigen Relapse Free Survival; PSA: Prostate Specific Antigen; PTV: Planning target volume; RCS: Rectum Cross Section

Acknowledgements
The authors thank dr Xin Pei, PhD, for technical support.

Funding
This research was partially supported by the MSK Cancer Center Support Grant/Core Grant (P30 CA008748). PMR was supported by the Danish Cancer Foundation. PG was supported financially by the Swiss Foundation for Medical-Biological Scholarships (SSMB) as well as the Eugen & Elisabeth Schellenberg Foundation.

Availability of data and materials
Some data are presented as part of the supplement. Please contact the senior author (dr. Deasy) for data requests.
by the bias of rectal distension in prostate cancer treatment planning: clinical evidence. Int J Radiat Oncol Biol Phys. 2012;83(3):947–52.

12. Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys. 2006;64(2):385–91.

13. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125–9.

14. Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, et al. Late side effects after image guided intensity-modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. 2016;95(2):680–9.

15. Sweijtrup J, af Rosenschold PM, Deasy JO, Oh JH, Pomerantsev PM, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014;9:44.

16. Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol. 2009;55(1):87–99.

17. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun FK, Schlom T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2000;163(3 Pt 1):939–44. discussion 44.

18. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys. 2006;65(4):999–1007.

19. Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology. 2000;55(3):382–6.

20. Zhang M, Moliseenko V, Liu M, Craig T. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: result of organ motion simulations. Phys Med Biol. 2006;51(2):269–85.

21. Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for radiotherapy research. Med Phys. 2003;30(5):979–85.

22. Munck Af Rosenschold P, Desai NB, Oh JH, Apte A, Hunt M, Kalikstein A, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Phys Med Biol. 2009;55(5):979–85.

23. Heemskerken WD, Al-Mamgani A, Witte MG, van Hek M, Lebesque JV. Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: results from a randomized trial. Radiother Oncol. 2013;107(2):334–9.

24. Witte MG, Heemskerken WD, Bohoslavsky R, Pos FJ, Al-Mamgani A, Lebesque JV, et al. Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy vs. 78 Gy. Int J Radiat Oncol Biol Phys. 2010;77(1):131–8.

25. van der Burgt M, Bergsma L, de Vries J, Pos FJ, Kalisvaart R, Heemskerken W, et al. Impact of tumour invasion on seminal vesicles mobility in radiotherapy of prostate cancer. Radiother Oncol. 2015;117(2):283–7.

26. Butter WM, Merrick GS, Reed JL, Murray BC, Kurko BS. Intrafraction displacement of prone versus supine prostate positioning monitored by real-time electromagnetic tracking. J Appl Clin Med Phys. 2013;14(2):1411.

27. Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skvarchuk MW, Schlegel W, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol. 2002;63(1):11–26.

28. Bayley AJ, Catton CN, Haycocks T, Kelly V, Alasti H, Bitew R, et al. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother Oncol. 2004;70(1):37–44.

29. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1146–50.

30. Dinh CV, Steenbergen P, Ghobadi G, Hjelmink SW, Pos FJ, Haustermans K, et al. Magnetic resonance imaging for prostate cancer radiotherapy. Phys Med. 2016;32(3):446–51.